Acute kidney injury due to deferoxamine in a renal transplant patient

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 1061-1064

  Clajus, Christian ^a   Becker, Jan U ^a   Stichtenoth, Dirk O ^a   Wortmann, Jessica ^a   Schwarz, Anke ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic kidney disease; Deferoxamine; Renal biopsy; Toxicity

Indexed keywords

BENZBROMARONE; CANDESARTAN; CARVEDILOL; CYCLOSPORIN A; DEFEROXAMINE; EZETIMIBE; FUROSEMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANTOPRAZOLE; PRAVASTATIN; PREDNISOLONE; VERAPAMIL; WARFARIN; IRON; SIDEROPHORE;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; GOODPASTURE SYNDROME; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRON OVERLOAD; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MACROCYTIC ANEMIA; MALE; PRIORITY JOURNAL; PROTEINURIA; SYMPTOM; ULTRASTRUCTURE; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY FAILURE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHEMICALLY INDUCED DISORDER; GLOMERULONEPHRITIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; DEFEROXAMINE; HUMANS; IRON; KIDNEY FAILURE, ACUTE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIDEROPHORES;

EID: 42449132604     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm824     Document Type: Article

References (13)

1. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
2. Windus DW, Stokes TJ, Julian BA et al. Fatal rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 1987; 107: 678-680
3. Batey R, Scott J, Jain S et al. Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scand J Haematol 1979; 22: 277-279
4. Cianciulli P, Sorrentino F, Forte L, et al. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haematologica 1992; 77: 514-515
5. Koren G, Kochavi-Atiya Y, Bentur Y et al. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol 1991; 54: 371-375
6. Cartei G, Barbui T, Cazzavillan M et al. Desferrioxamine B: reversible side effects of high daily doses. Blut 1975; 31: 11-16
7. Koren G, Bentur Y, Strong D et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989; 143: 1077-1080
8. Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV et al. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro. Biochem J 1988; 254: 239-244
9. Cianciulli P, Sollecito D, Sorrentino F et al. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int 1994; 46: 467-470
10. Yoon YS, Cho H, Lee JH et al. Mitochondrial dysfunction via disruption of complex II activity during iron chelation-induced senescence-like growth arrest of Chang cells. Ann N Y Acad Sci 2004; 1011: 123-132
11. Yoon YS, Byun HO, Cho H et al. Complex II defect via downregulation of iron-sulfur subunit induces mitochondrial dysfunction and cell cycle delay in iron chelation-induced senescence-associated growth arrest. J Biol Chem 2003; 278: 51577-51586
12. Olsen TS, Olsen HS, Hansen HE. Tubular ultrastructure in acute renal failure in man: epithelial necrosis and regeneration. Virchows Arch A Pathol Anat Histopathol 1985; 406: 75-89
13. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007; 6: 235-239